by Victoria Radke | Aug 12, 2021
The Food and Drug Administration (FDA) has approved Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia. Idiopathic hypersomnia is a rare neurological sleep disorder characterized by chronic excessive daytime...
by Victoria Radke | Aug 12, 2021
The Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus lenvatinib (Lenvima) for the treatment of advanced renal cell carcinoma (RCC). RCC is a kidney cancer that originates in the lining of the proximal convoluted tubule. Most cases of RCC...
by Victoria Radke | Aug 6, 2021
The Food and Drug Administration (FDA) has approved avalglucosidase alfa (Nexviazyme) for the treatment of late-onset Pompe disease in patients 1 year of age and older. Pompe disease is a lysosomal storage disorder caused by inadequate levels of the enzyme acid...
by Victoria Radke | Jul 20, 2021
The Food and Drug Administration (FDA) has approved odevixibat (odevixibat), the first drug approved for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that causes progressive, life-threatening liver disease due...
by Victoria Radke | Jul 20, 2021
The Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis. Dermatomyositis is a rare autoimmune disease...
